| abstract |
The present invention relates to a novel use of a sesquiterpene derivative and, more specifically, to a composition for preventing, alleviating, or treating macular degeneration or macular oedema caused by a vascular leakage in an eyeball, the composition comprising a sesquiterpene derivative compound represented by chemical formula 1 of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient. Intraocular disease-related treating agents on the market cause inconvenience because the treating agents should be directly intravitreally injected, and thus pain and side effects are caused. In contrast, the sesquiterpene derivative compound of the present invention is distributed to target tissue (an eye) through administration pathways (oral administration, intraperitoneal injection, and the like) other than intravitreal injection. Accordingly, the sesquiterpene derivative compound has therapeutic efficacy without being restricted by administration pathways, yielding excellent effects. |